Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
Edson D MoreiraNicholas KitchinXia XuSamuel S DychterStephen LockhartAlejandra C GurtmanJohn L PerezCristiano ZerbiniMichael E DeverTimothy W JenningsDonald M BrandonKevin D CannonMichael J KorenDouglas S DenhamMezgebe BerheDavid Fitz-PatrickLaura L HammittNicola P KleinHaylene NellGeorgina KeepXingbin WangKenneth KouryKena A SwansonDavid CooperClaire LuÖzlem TüreciEleni LagkadinouDina B TresnanPhilip R DormitzerUğur ŞahinWilliam C GruberKathrin U Jansennull nullPublished in: The New England journal of medicine (2022)
A third dose of the BNT162b2 vaccine administered a median of 10.8 months after the second dose provided 95.3% efficacy against Covid-19 as compared with two doses of the BNT162b2 vaccine during a median follow-up of 2.5 months. (Funded by BioNTech and Pfizer; C4591031 ClinicalTrials.gov number, NCT04955626.).